Lenny Van Steenhuyse
Lenny is an associate director at Oaklins KBC Securities in Belgium, with a focus on ECM and M&A in the biotech, medtech, healthtech and broader life sciences industry. He has been active in the sector for seven years, and has supported multiple biotech ECM transactions, including the Euronext IPOs of Sequana Medical, Hyloris Pharmaceuticals and MaaT Pharma, and the NASDAQ IPOs of Inventiva and MDx Health.
Prior to joining the firm’s corporate finance team in 2021, Lenny spent four years as a sell-side equity analyst at KBCS covering the biotech sector, including names such as Galapagos, Argenx and UCB. He has an MSc in Biochemistry & Biotechnology from Ghent University and a postgraduate degree in corporate finance from the Catholic University of Leuven.